Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Cure8 research brief
Why This Matters
A colon-targeted IFX formulation could deliver the drug directly to inflamed tissue, potentially improving effectiveness and lowering systemic side effects or dosing complexity for people with ulcerative colitis.
This research is at a preclinical stage but points to new delivery methods that may matter to patients using biologics.
Who Should Pay Attention
Clinicians treating UC, researchers in drug delivery and IBD therapeutics, and patients on or considering biologic therapy for ulcerative colitis.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
LMPs are a lipid-based gel platform designed to protect and release IFX at inflamed colon tissue; the study focuses on formulation design, physicochemical characterization, and preclinical efficacy. Rectal gels showed strong mucoadhesion; oral forms used enteric capsules or 3D printing to target the colon.
In animal prophylactic models, LMP-based IFX reduced inflammation more than subcutaneous IFX, suggesting improved local delivery could increase therapeutic effect and reduce systemic exposure. This is a preclinical (non-human) study reported in a journal abstract; it demonstrates a delivery approach rather than presenting clinical trial results.
More work including human trials would be required before clinical use.
Keep In Mind
The article is a preclinical/physicochemical and animal study (abstract level). Findings describe formulation performance and prophylactic efficacy in models, not human safety or effectiveness. Further clinical development and trials are needed before changes to treatment practice would be warranted.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAdvanced science (Weinheim, Baden-Wurttemberg, Germany)
AuthorsRafaela Gazzi, Tiziana Cremona, Reto Czekalla +11 more
InstitutionDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 11, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Probiotic‐Derived Vesicles Rectally Delivered via Thermo‐Gelling Copolymer Promote Mucosal Healing and Reduce Inflammation in Ulcerative Colitis
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
Colon-targeted oral delivery of melatonin for regulating macrophage activity and intestinal barrier in ulcerative colitis.
Targeted oral delivery of melatonin could reduce inflammation and help repair the intestinal barrier in UC by acting on macrophages and epithelial cells. If translated to humans, this approach might offer a locally...
Quaternized chitosan-based double-network hydrogel for oral precise delivery of Sinapic acid in ulcerative colitis therapy.
The study describes a novel hydrogel designed to deliver sinapic acid directly to the inflamed colon and release drug in response to a reducing environment—an approach that could improve targeted oral therapies for...